Physician profile
Jonathan Song
NPI 1902260227
$9,626.64
in general payments reported to CMS, 2019-2025
25 companies · $992 in 2025
The $992 reported for 2025 was more than what a typical Pain Medicine (Physical Medicine & Rehabilitation) provider received nationally (typical 2025 total: $400).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $594 · 2021: $477 · 2022: $1,940 · 2023: $2,974 · 2024: $2,649 · 2025: $992.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,446 · Education: $1,169.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,446.34 |
| Education | $1,169.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $3,073.68 | 2020-2024 | Senza, Omnia |
| Abbott Laboratories | $2,100.06 | 2022-2025 | Proclaim, Prodigy |
| Nalu Medical, INC. | $1,865.53 | 2023-2025 | Nalu Neurostimulation System |
| Vertos Medical, INC. | $753.26 | 2022-2024 | Mild Device Kit |
| Boston Scientific Corporation | $313.50 | 2021-2025 | Superion Indirect Decompression System, Wavewriter Alpha Prime 16, General - Pain Management |
| Medtronic, INC. | $225.30 | 2022-2025 | Inceptiv |
| Stryker Corporation | $224.19 | 2020-2024 | Mild Device Kit |
| Abbvie INC. | $204.14 | 2022 | |
| Foundation Fusion Solutions, LLC | $168.70 | 2023-2025 | |
| Medtronic USA, INC. | $140.18 | 2020 | |
| Avanos Medical | $124.86 | 2021 | |
| Pacira Therapeutics, INC. | $124.49 | 2021 | |
| Stimwave Technologies Incorporated | $62.05 | 2021 | |
| Amgen INC. | $31.27 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $30.40 | 2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Spr Therapeutics, INC | $27.10 | 2022 | |
| Grt US Holding, INC. | $26.15 | 2022 | |
| Collegium Pharmaceutical, INC. | $22.70 | 2022 | |
| Valinor Pharma, LLC | $22.18 | 2023 | Movantik |
| Teva Pharmaceuticals USA, INC. | $21.03 | 2022 | |
| Bioventus LLC | $19.74 | 2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $17.16 | 2022 | |
| Acacia Pharma INC | $15.11 | 2022 | |
| Hikma Pharmaceuticals USA | $13.86 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Song listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.